ESC Professional Premium Access

Cardiovascular risk assessment & COVID

Event: ESC Congress 2022
Topic: Cardiovascular Risk Assessment
Session type: Moderated ePosters
Date: 28 August 2022
Time: 08:15 - 09:00

Congress Session

6 presentations in this session

Prognostic implications of cardiac 82-rubidium positron emission tomography in angina patients with no perfusion defects

Speaker: Ms M. Rauf (Copenhagen, DK)
Thumbnail

Acute effects of COVID-19 vaccination on inflammatory, macrovasular and microvascular biomarkers

Speaker: Doctor D. Terentes-Printzios (Athens, GR)
Thumbnail

High sensitivity troponin I and newly/recently diagnosed coronavirus-19 disease patients presenting to the emergency department: values above and below the 99th percentile predict 28 day mortality

Speaker: Professor R. Nowak (Detroit, US)
Thumbnail

Classic and genetic cardiovascular risk burden and case-fatality from SARS-CoV-2 virus infection. The CARGENCORS study.

Speaker: Ms A. Camps-Vilaro (Barcelona, ES)
Thumbnail

Prediction of clinical outcomes in patients with coronavirus disease 2019 using high-sensitive troponin I and N-terminal pro-B-type natriuretic peptide

Speaker: Doctor M. Sano (Kobe, JP)
Thumbnail

Does the quality index of adherence to the evidence-based guidelines predict mortality in patients with myocardial infarction?

Speaker: Mr T. Gudmundsson (Gothenburg, SE)
Thumbnail

6 speakers from this session

Ms Maira Rauf

Bispebjerg Hospital, Copenhagen (Denmark)
1 follower

Doctor Dimitrios Terentes-Printzios

National & Kapodistrian University of Athens, Athens (Greece)
1 presentation
0 follower

Professor Richard Michael Nowak

Henry Ford Health System, Detroit (United States of America)
0 follower

Ms Anna Camps-Vilaro

Hospital del Mar Medical Research Institute (IMIM), Barcelona (Spain)
0 follower

Doctor Madoka Sano

Kobe City Medical Center General Hospital, Kobe (Japan)
0 follower

Mr Thorsteinn Gudmundsson

Sahlgrenska University Hospital, Gothenburg (Sweden)
0 follower

This platform is supported by

logo Novo Nordisk